ArticleJournal of assisted reproduction and genetics2016
Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing.
Article in Journal of assisted reproduction and genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 256 citations in OpenAlex.
- The ethics of clinical applications of germline genome modification: a systematic review of reasons.Human reproduction (Oxford, England) · 2018Pooled it
- The multi-omics regulatory landscape of human early embryogenesis.Cellular and molecular life sciences : CMLS · 2026Review
- Review
- Exosomes for CRISPR-Cas9 Delivery: The Cutting Edge in Genome Editing.Molecular biotechnology · 2024Review
- Governing with public engagement: an anticipatory approach to human genome editing.Science & public policy · 2024Article
- Emerging Medical Technologies and Their Use in Bionic Repair and Human Augmentation.Bioengineering (Basel, Switzerland) · 2024Review
- Developmental progression of DNA double-strand break repair deciphered by a single-allele resolution mutation classifier.Nature communications · 2024Article
- CRISPR/Cas9 technology: applications in oocytes and early embryos.Journal of translational medicine · 2023Review
- Researching the future: scenarios to explore the future of human genome editing.BMC medical ethics · 2023Article
- The history, use, and challenges of therapeutic somatic cell and germline gene editing.Fertility and sterility · 2023Review
- Base editors: development and applications in biomedicine.Frontiers of medicine · 2023Review
- Article
- Nanoparticle-mediated genome editing in single-cell embryos via peptide nucleic acids.Bioengineering & translational medicine · 2023Article
- Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.Military Medical Research · 2023Review
- Ethical Perspectives of Therapeutic Human Genome Editing From Multiple and Diverse Viewpoints: A Scoping Review.Cureus · 2022Article
- Human embryonic genome activation initiates at the one-cell stage.Cell stem cell · 2022Article
- Detection of CCR5Δ32 Mutant Alleles in Heterogeneous Cell Mixtures Using Droplet Digital PCR.Frontiers in molecular biosciences · 2022Review
- AttCRISPR: a spacetime interpretable model for prediction of sgRNA on-target activity.BMC bioinformatics · 2021Article
- Excluding embryos with two novel mutations inAging · 2021Article
- Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAs a powerful technology for genome engineering, the CRISPR/Cas system has been successfully applied to modify the genomes of various species. The purpose of this study was to evaluate the technology and establish principles for the introduction of precise genetic modifications in early human embryos.
methods3PN zygotes were injected with Cas9 messenger RNA (mRNA) (100 ng/μl) and guide RNA (gRNA) (50 ng/μl). For oligo-injections, donor oligo-1 (99 bp) or oligo-2 (99 bp) (100 ng/μl) or dsDonor (1 kb) was mixed with Cas9 mRNA (100 ng/μl) and gRNA (50 ng/μl) and injected into the embryos.
resultsBy co-injecting Cas9 mRNA, gRNAs, and donor DNA, we successfully introduced the naturally occurring CCR5Δ32 allele into early human 3PN embryos. In the embryos containing the engineered CCR5Δ32 allele, however, the other alleles at the same locus could not be fully controlled because they either remained wild type or contained indel mutations.
conclusionsThis work has implications for the development of therapeutic treatments of genetic disorders, and it demonstrates that significant technical issues remain to be addressed. We advocate preventing any application of genome editing on the human germline until after a rigorous and thorough evaluation and discussion are undertaken by the global research and ethics communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.